• Users Online: 536
  • Print this page
  • Email this page
Year : 2020  |  Volume : 4  |  Issue : 3  |  Page : 259-265

Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia

Department of Pharmacology, Toxicology and Medicine, College of Medicine Almustansiriya University, Baghdad, Iraq

Correspondence Address:
Dr. Hayder M Al-Kuraishy
Department of Pharmacology, Toxicology and Medicine, College of Medicine Almustansiriya University, P.O. Box: 14132, Baghdad
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/bbrj.bbrj_26_20

Rights and Permissions

Background: Dyslipidemia (DL) is a blood lipid disorder characterized by high cholesterol, triglyceride and low density lipoprotein with reduction of high density lipoprotein. Crataegus Oxyacantha hawthorn (COH) is used in treatment of hyperlipidemia , hypertension , angina pectoris and arrhythmia as alternative medicine . The aim of the present study was to evaluate the effect of fenofibrate alone or in combination with Crataegus Oxyacantha on lipid profile in patients with mixed dyslipidemia. Methods: A total number of 64 patients with MD on fenofibrate therapy compared to 24 healthy controls were recruited and randomized into three groups: Group A: (control, n = 24) not received any lipid-lowering agents, Group B: (fenofibrate, n = 30) received fenofibrate 200 mg/day for 10 weeks, and Group C: (combination, n = 34) received fenofibrate 200 mg/day plus C. oxycantha for 10 weeks. The estimation of lipid profile and blood pressure changes were done at baseline and following 10 weeks of therapy. Results: Following 10 weeks of C. oxycantha add on fenofibrate therapy, there was a significant reduction on total cholesterol, triglyceride, non-high-density lipoprotein-cholesterol AI, and low-density lipoprotein plasma levels compared with fenofibrate-treated patients (P < 0.05). Blood pressure profile showed more significant reduction in patients with dyslipidemia (DL) treated with C. oxycantha compared with baseline data and with patients with DL treated with fenofibrate alone (P < 0.05). Fenofibrate plus C. oxycantha showed more significant reduction on high-sensitive C-reactive protein serum levels from 5.28 ± 1.61 mg/dL to 2.74 ± 1.99 mg/dL, P < 0.0001. Conclusion: C. oxycantha synergized the effect of fenofibrate therapy in patients with MD through the improvement of lipid profile and attenuation of endothelial inflammation.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded101    
    Comments [Add]    

Recommend this journal